+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 50Years +
All Genders
ID07007065

Randomized Study Evaluating Safety, Injection Burden, and Vision Outcomes of Surabgene Lomparvovec Versus Ranibizumab in Adults with Neovascular Age-Related Macular Degeneration

Led by AbbVie · Updated on 2026-10-29

561

Participants Needed

138

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Neovascular age-related macular degeneration nAMD, often called wet AMD, involves abnormal growth of new blood vessels in the retina, the light-sensitive tissue at the back of the eye. This research aims to evaluate the safety and effectiveness of Surabgene Lomparvovec, an investigational gene therapy, in adults aged 50 and older who have been previously treated for nAMD. Approximately 561 participants will be enrolled globally and randomized into three groups to compare different treatments. Participants will be assigned to one of three groups two groups receive a single subretinal injection of Surabgene Lomparvovec at different doses, and the third group receives Ranibizumab injections as needed throughout the study. Ranibizumab is given as an intravitreal injection into the jelly-like tissue inside the eye, while Surabgene Lomparvovec is delivered beneath the retina. The studys assessment period begins two weeks before randomization and follows participants for up to five years. During the study, participants will attend monthly visits at a hospital or clinic where medical assessments, blood tests, side effect monitoring, and questionnaires will be conducted to evaluate treatment effects. Researchers will track the annual rate of anti-VEGF injections and monitor adverse events over five years, along with changes in visual acuity. The study is designed to assess long-term treatment burden, safety, and preservation of vision in a real-world context.

CONDITIONS

Brief Title

Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)

Research Team

A

ABBVIE CALL CENTER

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here